Can biosimilars save billions in health care spending? A new report says yes. Analyses conducted by the Pacific Research Institute suggest that a 25% gain in biosimilar market share could save $2.5billion in spending, with further increases in market share projected to result in further savings.
Want to dig deeper into biosimilars?
-
Article
Biosimilars in Canada: Regulatory and Health System Approaches
Read Now
Megan Bettle, Health Canada
Global Forum -
Article
Interchangeable Biosimilars: EU and US Experiences and Perspectives
Read Now
Chris Slawecki, DIA
Global Forum -
Article
Patients, Price, and Profit: Are Incentives in Balance for Orphan Drugs?
Read Now
Adam Hutchings, Dolon Ltd.
Global Forum -
Article
The Benefits Of Real-World Evidence (RWE) For Biosimilars And Special Populations
Read Now
Sandra Blumenrath and Ranjini Prithviraj, DIA
Clinical Leader -
Article
Sample Size for Biosimilar Trials: In Defense of Synthesis
Read Now
Timothy Clark, Sook Jung Jo, and Alan Phillips
Therapeutic Innovation & Regulatory Science
Member-only content
-
Article
FDA Expectations for Demonstrating Interchangeability
Read Now
Kamali Chance
Therapeutic Innovation & Regulatory Science
Member-only content
-
Podcast
Biosimilars' Good News for Patients
Listen Now
Cecil Nick -
Video Interview
Biosimilar Interchangeability
Watch Now
Nielsen Hobbs
Want to learn more?
Attend our upcoming Biosimilars Conference in September, in Bethesda, MD or the DIA North Africa Regulatory Conference in October, in Cairo!